Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Dermatology and Therapy |
| Online Access: | https://doi.org/10.1007/s13555-024-01328-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724012948619264 |
|---|---|
| author | Richard B. Warren Lev Pavlovsky Antonio Costanzo Michael Bukhalo Neil J. Korman Yu-Huei Huang Georgios Kokolakis Andreas Pinter Nadia Ibrahim Yanbing Zheng Leonidas Drogaris Vassilis Stakias Ahmed M. Soliman Simone Rubant Diamant Thaçi |
| author_facet | Richard B. Warren Lev Pavlovsky Antonio Costanzo Michael Bukhalo Neil J. Korman Yu-Huei Huang Georgios Kokolakis Andreas Pinter Nadia Ibrahim Yanbing Zheng Leonidas Drogaris Vassilis Stakias Ahmed M. Soliman Simone Rubant Diamant Thaçi |
| author_sort | Richard B. Warren |
| collection | DOAJ |
| format | Article |
| id | doaj-art-4f93bbbdedfc4c43a55fd2a5ca002609 |
| institution | DOAJ |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-4f93bbbdedfc4c43a55fd2a5ca0026092025-08-20T03:10:52ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-01-0115247748110.1007/s13555-024-01328-4Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B. Warren0Lev Pavlovsky1Antonio Costanzo2Michael Bukhalo3Neil J. Korman4Yu-Huei Huang5Georgios Kokolakis6Andreas Pinter7Nadia Ibrahim8Yanbing Zheng9Leonidas Drogaris10Vassilis Stakias11Ahmed M. Soliman12Simone Rubant13Diamant Thaçi14The Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Salford Royal NHS Foundation TrustSackler Faculty of Medicine, Tel Aviv UniversityDepartment of Biomedical Sciences, Humanitas UniversityArlington DermatologyDepartment of Dermatology, University Hospitals Cleveland Medical Center and Case Western Reserve UniversityDepartment of Dermatology, Linkou Branch, Chang Gung Memorial HospitalPsoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Dermatology, University Hospital Frankfurt am MainAbbVie Inc.AbbVie Inc.AbbVie Inc.AbbVie Inc.AbbVie Inc.AbbVie DeutschlandInstitute and Comprehensive Center Inflammation Medicine, University of Lübeckhttps://doi.org/10.1007/s13555-024-01328-4 |
| spellingShingle | Richard B. Warren Lev Pavlovsky Antonio Costanzo Michael Bukhalo Neil J. Korman Yu-Huei Huang Georgios Kokolakis Andreas Pinter Nadia Ibrahim Yanbing Zheng Leonidas Drogaris Vassilis Stakias Ahmed M. Soliman Simone Rubant Diamant Thaçi Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study Dermatology and Therapy |
| title | Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study |
| title_full | Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study |
| title_fullStr | Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study |
| title_full_unstemmed | Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study |
| title_short | Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study |
| title_sort | correction efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab results from a phase 3b open label single arm aimm study |
| url | https://doi.org/10.1007/s13555-024-01328-4 |
| work_keys_str_mv | AT richardbwarren correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT levpavlovsky correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT antoniocostanzo correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT michaelbukhalo correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT neiljkorman correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT yuhueihuang correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT georgioskokolakis correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT andreaspinter correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT nadiaibrahim correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT yanbingzheng correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT leonidasdrogaris correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT vassilisstakias correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT ahmedmsoliman correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT simonerubant correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy AT diamantthaci correctionefficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy |